IN THIS ISSUE

Michael Levin-Epstein

Kenneth Coburn, MD, MPH

They’re customized to local caseloads and conditions, they coordinate with primary care practices, and they focus on building trust with patients
Focus on Biologics
Thomas Reinke

David Veenstra, PharmD, PhD

Health plans often have to gauge the value of genetic and genomic tests and are forced to make decisions with imperfect information
Biologics In Development
Katherine T. Adams
ACO Update
Peter Wehrwein
Hospital-led ACOS may have some advantages in the beginning, but the physician group ACOs may win out in the long run
Legislation & Regulation
Richard Mark Kirkner

Paul Ginsburg, PhD

Voters overwhelmingly approved an any-willing-provider law, striking a blow against narrow networks
Medication Management
Thomas Reinke
Experts at three PBMs say watch out for several recently approved and expected-to-be-approved medications
The Formulary Files
Krishna Rutvij Patel, PharmD
Medical Device Monitor
Katherine T. Adams
Report suggests that greater attention to cost-effectiveness, quality, and regulatory issues will force the industry to demonstrate value and be nimble
Tomorrow's Medicine
Thomas Morrow, MD

Thomas Morrow, MD

While both pirfenidone and nintedanib bolster lung function for this fatal disease, they do not improve survival rates
News & Commentary
News & Commentary
Frank Diamond